AC
KZR

Amia Capital’s Kezar Life Sciences KZR Stock Holding History

Amia Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,315
Closed -$112K – 19
2020
Q3 		$112K Buy
2,315
+1,004
+77% +$48K 0.13% 34
2020
Q2 		$68K Sell
1,311
-41
-3% -$2.07K 0.06% 37
2020
Q1 		$59K Buy
+1,352
New +$55K 0.05% 38

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Amia Capital's KZR Position: Q4 2020 in Review

Amia Capital sold out of Kezar Life Sciences (KZR) in Q4 2020, closing a stake of 2,315 shares — an estimated $112K sold.

Amia Capital first reported a position in KZR in Q1 2020 and held it in 3 quarters. The position peaked at $112K in Q3 2020. 77 funds tracked by Wall St. Rank hold KZR as of Q4 2020.

  • Amia Capital reported no remaining Kezar Life Sciences position as of Q4 2020 after selling out during the quarter.
  • Amia Capital sold 2,315 Kezar Life Sciences shares in Q4 2020, an estimated $112K.
  • Amia Capital first reported a position in Kezar Life Sciences in Q1 2020 and held it in 3 quarters.
  • Amia Capital's Kezar Life Sciences position peaked at $112K in Q3 2020.
  • 77 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2020.

Based on Amia Capital's 13F filing for Q4 2020, filed 11 Feb 2021.